北陸藥業(300016.SZ):釓噴酸葡胺注射液取得藥品補充申請批件
格隆匯6月29日丨北陸藥業(300016.SZ)宣佈,公司近日取得國家藥品監督管理局核准簽發的關於公司釓噴酸葡胺注射液的藥品補充申請批件。申請內容為申請釓噴酸葡胺注射液與公司自制的葡甲胺(登記號:F20190000356)進行關聯審評,增加公司自制葡甲胺為公司釓噴酸葡胺注射液葡甲胺輔料的供應商。
公司表示,此次公司申請釓噴酸葡胺注射液與公司自制的葡甲胺進行關聯審評並通過,標誌着公司自制葡甲胺可作為輔料用於公司釓噴酸葡胺注射液的生產,對公司確保產品穩定持續生產、成本控制等具有積極意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.